Sun Pharmaceutical Industries' stock surged by 7% following its announcement of acquiring Organon & Co. for $11.75 billion, marking the largest overseas acquisition by an Indian pharmaceutical firm. However, concerns over growth visibility and high debt at Organon may limit future gains.

• 01Sun Pharma's stock rose 7% after announcing the acquisition of Organon & Co.
• 02The acquisition is valued at $11.75 billion, the largest for an Indian pharma company.
• 03Despite the acquisition, growth visibility at Organon raises concerns.
• 04High debt levels at Organon may cap potential gains for Sun Pharma.
• 05The deal highlights the synergy potential but also the risks involved.

The acquisition could lead to enhanced product offerings for consumers, but concerns about Organon's debt may affect future pricing and availability.